Cost-Outcome Description of PEG-IFN-α2b+RBV for Hepatitis C: Results Based on the Interferon Database

摘要: Economic evaluation of drugs is used in decision-making on medical care and public policy. Recently, real-world data (RWD) have been the analysis. In this study, we discuss risk benefits using RWD for economic evaluation. We conducted a cost-outcome description with from nationwide registry providing information hepatitis treatment Japan estimated utility evaluated peginterferon plus ribavirin (PEG-IFN-α2b+RBV) C virus (HCV)-infected patients. Simulations were based Markov model. The cohorts set assumed societal perspective calculation costs. dose drug cost chosen Japanese Guidelines Management Hepatitis Virus Infection or package inserts. Model details parameters as described previous studies. simulations performed period 10 years no discount rate. 2.5 million JPY per Quality Adjusted Life Year (QALY) 48-week PEG-IFN-α2b+RBV years. results study are agreement HCV studies Japan. analyzed statistics HCV-infected patients at each disease stage our calculated more closely reflect clinical situation compared to widely randomized trial method, which estimates scenarios.